| 中文名称 | 3-AMINO-1-PROPANESULFONIC ACID(3-氨基丙烷磺酸) |
| 英文名称 | 1-?Propanesulfonic acid, 3-?amino- |
| CAS号 | 3687-18-1 |
| 分子式 | C3H9NO3S |
| 分子量 | 139.17 |
| EINECS号 | 222-977-4 |
| 熔点 | 293 °C (dec.)(lit.) |
| 密度 | 1.202 (estimate) |
| 折射率 | 1.5130 (estimate) |
| LogP | -4.555 |
| 溶解度 | 可微溶于水 |
| 形态 | 结晶粉末 |
| 酸度系数(pKa) | 1.06±0.50(Predicted) |
| 颜色 | 白色至略带蓝色 |
| 危险品标志 | Xi |
| 危险类别码 | 36/37/38 |
| 安全说明 | 26-36 |
| WGK Germany | 1 |
| 海关编码 | 29049090 |
| Target | Value |
|
GABA receptor
() |
Tramiprosate (200 μg/mL, 40 μg/mL, 8 μg/mL and 1.6 μg/mL; 1 hours) significantly attenuates oxygen/glucose deprivation (OGD)- or NMDA-induced injury in NGF-differentiated PC12 cells and primary cortical neurons. Tramiprosate decreases the intensity of the association between nNOS and PSD95, and Tramiprosate also inhibits the translocation of nNOS from the cytosol to the membrane.
Tramiprosate (6.25-50 mg/kg; intraperitoneal injection; once) treatment dose-dependently reduces the infarct volume after MCAO. Tramiprosate (50 mg/kg) treatment shows a significant neurological functional recovery.
| Animal Model: | Adult male Sprague-Dawley rats (200-250 g) subjected to middle cerebral artery occlusion (MCAO) |
| Dosage: | 50 mg/kg, 25 mg/kg, 12.5 mg/kg or 6.25 mg/kg |
| Administration: | Intraperitoneal injection; once |
| Result: | Dose-dependently reduced the infarct volume after MCAO. |